Global Neurosarcoidosis Treatment Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Neurosarcoidosis Treatment Market Research Report 2024
Neurosarcoidosis is the type of chronic inflammatory disease that is characterized by the formation of granulomas. It affects several parts of the body and internal organs such as lungs, brain, lymph nodes, spinal cord and others. Patients suffering from confusion, headaches, inability or change in ability to smell or taste, psychiatric issues, seizures, hallucinations, and speech difficulties are the majorly susceptible to this condition.
According to Mr Accuracy reports’s new survey, global Neurosarcoidosis Treatment market is projected to reach US$ 7114 million in 2029, increasing from US$ 5370 million in 2022, with the CAGR of 4.1% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Neurosarcoidosis Treatment market research.
Sarcoidosis is a worldwide disease affecting all races, ages, and genders. 70% of patients are between 25 and 45 years old. In Europe and Japan, women over the age of 50 are the second highest incidence of sarcoidosis. The onset is rare in those younger than 15 or older than 70. Most studies show that the prevalence of women is slightly higher, and the incidence rate is increasing. The average onset age of NS is between 33 and 41 years old, which is later than other types of sarcoidosis. About 50% of patients have systemic diseases, and 30%-70% have neurological symptoms. All systems of sarcoidosis have a mortality rate of 1% to 5% due to pulmonary, cardiac, or neurologic involvement.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Neurosarcoidosis Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Hikma Pharmaceuticals PLC
Mylan N.V.
Amneal Pharmaceuticals LLC
Mallinckrodt
AbbVie Inc
Pfizer Inc
Sandoz International GmbH
Teva Pharmaceuticals
F. Hoffmann-La Roche Ltd
Fresenius Kabi USA
Merck & Co.，Inc
Vintage Labs
Taro Pharmaceutical Industries Ltd
Jubilant Cadista Pharmaceuticals Inc
Horizon Therapeutics plc
Segment by Type
Oral
Extraintestinal
Hospitals
Specialty Clinics
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Neurosarcoidosis Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Neurosarcoidosis Treatment market is projected to reach US$ 7114 million in 2029, increasing from US$ 5370 million in 2022, with the CAGR of 4.1% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Neurosarcoidosis Treatment market research.
Sarcoidosis is a worldwide disease affecting all races, ages, and genders. 70% of patients are between 25 and 45 years old. In Europe and Japan, women over the age of 50 are the second highest incidence of sarcoidosis. The onset is rare in those younger than 15 or older than 70. Most studies show that the prevalence of women is slightly higher, and the incidence rate is increasing. The average onset age of NS is between 33 and 41 years old, which is later than other types of sarcoidosis. About 50% of patients have systemic diseases, and 30%-70% have neurological symptoms. All systems of sarcoidosis have a mortality rate of 1% to 5% due to pulmonary, cardiac, or neurologic involvement.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Neurosarcoidosis Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Hikma Pharmaceuticals PLC
Mylan N.V.
Amneal Pharmaceuticals LLC
Mallinckrodt
AbbVie Inc
Pfizer Inc
Sandoz International GmbH
Teva Pharmaceuticals
F. Hoffmann-La Roche Ltd
Fresenius Kabi USA
Merck & Co.，Inc
Vintage Labs
Taro Pharmaceutical Industries Ltd
Jubilant Cadista Pharmaceuticals Inc
Horizon Therapeutics plc
Segment by Type
Oral
Extraintestinal
Segment by Application
Hospitals
Specialty Clinics
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Neurosarcoidosis Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices